Amicus Therapeutics, Inc.
FOLD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,867,269 | $4,188,384 | $3,529,388 | $3,134,924 |
| - Cash | $213,752 | $246,994 | $148,813 | $245,197 |
| + Debt | $443,644 | $445,059 | $452,120 | $440,129 |
| Enterprise Value | $3,097,161 | $4,386,449 | $3,832,695 | $3,329,856 |
| Revenue | $528,295 | $399,356 | $329,233 | $305,514 |
| % Growth | 32.3% | 21.3% | 7.8% | – |
| Gross Profit | $475,352 | $362,030 | $290,634 | $271,048 |
| % Margin | 90% | 90.7% | 88.3% | 88.7% |
| EBITDA | $29,389 | -$92,079 | -$199,578 | -$202,874 |
| % Margin | 5.6% | -23.1% | -60.6% | -66.4% |
| Net Income | -$56,106 | -$151,584 | -$236,568 | -$250,460 |
| % Margin | -10.6% | -38% | -71.9% | -82% |
| EPS Diluted | -0.18 | -0.51 | -0.82 | -0.92 |
| % Growth | 64.7% | 37.8% | 10.9% | – |
| Operating Cash Flow | -$33,891 | -$69,091 | -$166,575 | -$202,491 |
| Capital Expenditures | -$3,553 | -$7,440 | -$3,766 | -$3,884 |
| Free Cash Flow | -$37,444 | -$76,531 | -$170,341 | -$206,375 |